INTRODUCTION
============

The first description of neuroglia was made by Rudolf Virchow as a \'substance... which lies between the proper nervous parts, holds them together and gives the whole its form in a greater or lesser degree\' ([@B200]). The original concept of glia being just a goo soon after was refined to rather receive cellular attributes, as glial cells were stained using \'reazione nera\' and visualized by Camillo Golgi ([@B62]). A subset of these cells was termed astrocytes by Michael von Lenhossek ([@B101]). Interestingly, the gold chloride stain, used by Santiago Ramón y Cajal in 1913 to visualize astrocytes, targets IFs (intermediate filaments; [@B89]), which consist mainly of GFAP (glial fibrillary acidic protein) that is today used as an astrocytic marker, while its promoter became a prime tool in molecule genetics approaches (e.g. [@B143]; [@B30]) to study the role of astrocytes in the operation of the brain. It is at the beginning of the 20th century that glial research was pushed aside to a great extent by the victory of the neuronal doctrine with neurons being the sole determinant of the brain signalling. Of course, the fact that glial cells lack classical electrical excitability was a contributing factor. Following somewhat less than three quarters of a century of neglect, there has begun a period of about the past three decades during which extraordinary evidence has mounted to present astrocytes as an integral component of the brain operation. Owing to the development of fluorescent Ca^2+^ indicators, with non-disruptive intracellular loading, for optical measurements of cellular free Ca^2+^ ([@B189], [@B190]; [@B68]; [@B118]), in 1990, [@B35] made a seminal observation that activation of GluRs (glutamate receptors) in astrocytes raised their cytosolic Ca^2+^ levels. This finding was expanded to the observation that astrocytes with their Ca^2+^ responsiveness have the ability to \'sense\' glutamatergic synaptic transmission ([@B38]). This was followed by the discovery that astrocytic Ca^2+^ dynamics can yield astrocyte--neuron signalling, with two initial studies immediately pointing to the complexity of this intercellular communication by describing two divergent underlying mechanisms: direct, perhaps using gap junctions ([@B125]); and indirect utilizing glutamate released from astrocytes via Ca^2+^-dependent exocytosis ([@B138]). The later path has led to the discovery of gliotransmission-based modulation of synaptic transmission ([@B3]) and formulation of the concept that three, pre- and post-synaptic neuronal along with glial elements constitute a synapse ([@B88]), whose structural--functional partnership was termed the tripartite synapse ([@B5]). An additional level of complexity in the role of gliotransmission was then the finding that the Ca^2+^-dependent release of vasoactive agents from astrocyte endfeet is at the basis of neurovascular coupling ([@B213]) and that vesicles carrying gliotransmitters are subject to regulation ([@B179]). This represents the current view of synaptic physiology where astrocytes are actively involved in the brain\'s computational power. The aim of this review is to highlight up-to-date newer findings with respect to Ca^2+^ signalling in astrocytes and gliotransmission. We start with the description of Ca^2+^ sources and sinks that provide the astrocytic intracellular Ca^2+^ dynamics necessary and sufficient for regulation of exocytotic release of gliotransmitters. This is followed by a discussion on secretory machinery which underlies this release mechanism, and a description of secretory vesicles in astrocytes. It is the traffic of these organelles throughout the astrocyte which ultimately results in vesicular fusion to the plasma membrane that liberates gliotransmitter(s) into the ECS (extracellular space). It should be noted, however, that exocytosis also acts as a delivery route for insertion and retrieval of, for instance, receptors at the plasma membrane. Subsequently, we discuss exocytotic gliotransmission in modulation of synaptic transmission and plasticity, as well as astrocytic contribution to sleep behaviour. Finally, we describe the consequences of astrocytic Ca^2+^ excitability in epilepsy, as an example of a brain disorder with astrocytes as an aetiology share holder.

Astroglial Ca^2+^ excitability: Ca^2+^ sources and sinks
--------------------------------------------------------

Calcium, rather than electrical, signalling is generally considered a substrate for glial excitability ([@B41]; [@B198]; [@B1]). Calcium intracellular signalling system is present in virtually all living cells, being highly evolutionarily conserved ([@B29]; [@B199]). In eukaryotes, Ca^2+^ signalling can couple input to output, i.e. plasma membrane excitation to muscle contraction, metabolic reactions, gene expression and secretion. The excitation--secretion coupling that occurs through regulated exocytosis provides the basis for chemical transmission in the nervous system (reviewed in [@B137]). Astrocytes, the main homoeostatic cells in the CNS (central nervous system), are no exception to this eukaryotic evolutionary trait (reviewed in [@B135]). The Ca^2+^ signalling system involves several sets of molecules that generate Ca^2+^ concentration gradients, and provide pathways for Ca^2+^ diffusion between various cellular compartments, which serve as sources and/or sinks for this ion. Cell stimulation triggers concerted activation of these molecular sets that produce a spatio-temporally organized transient increase in the \[Ca^2+^\]~i~ (cytosolic/intracellular Ca^2+^ levels), which is sufficient and necessary for the engagement of Ca^2+^-sensitive effectors protein(s) of the secretory machinery. Subsequently, this leads to vesicular fusion to the plasma membrane liberating transmitters into the ECS, a process that has been referred to as gliotransmission when occurring in astrocytes. Below we summarize the role of several compartments, the ER (endoplasmic reticulum), ECS and mitochondria, for gliotransmission, in particular for Ca^2+^-dependent release of glutamate from astrocytes. The portrayal of this subject is largely driven by results obtained *in vitro*, although the final corroboration awaits further experimentation using more intact preparations.

The ER represents a dynamic network of tubules and cisternae distributed throughout the cell body, forming the nuclear envelope and extending towards most distal processes ([@B12]; [@B195]). One of the ER functions is to act as a dynamic Ca^2+^ store that generates and shapes cytosolic Ca^2+^ signals. The ER has its own Ca^2+^ homoeostatic machinery represented by: (i) Ca^2+^ pumps of SERCA (sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase) type that transport Ca^2+^ into the ER lumen against the concentration gradient; (ii) opposing leakage pathway from the ER ([@B27]; [@B13]); and (iii) Ca^2+^ release channels. The latter are archetypal ligand-gated channels, InsP~3~Rs (inositol 1,4,5-trisphosphate receptors) and RYRs (ryanodine/caffeine receptors), activated by the second messengers InsP~3~ and Ca^2+^ ions respectively ([@B16]; [@B58]; [@B71]), which when open allow Ca^2+^ release down its concentration gradient resulting in transient cytosolic Ca^2+^ signals. The host of metabotropic receptors expressed at the astrocytic plasma membrane activate the phospholipase C/InsP~3~ signalling cascade that results in the opening of InsP~3~Rs ([@B15]; [@B95]; [@B150]), which has been demonstrated in all types of glial cells *in vitro* and *in situ* (see e.g. [@B116]; [@B87]; [@B57]; [@B91], [@B92]; [@B145]; [@B198]; [@B1]). Although the role for RyRs in shaping Ca^2+^ release in astrocytes *in vivo* remains debatable ([@B136]), there are some indices of their contribution to the physiology of astrocytes, for instance, in ventrobasal thalamus ([@B139]).

The contribution of the ER Ca^2+^ release to gliotransmission was deduced from experiments on cultured astrocytes, which showed that inhibition of ER Ca^2+^ accumulation by thapsigargin, a specific SERCA blocker, largely reduced Ca^2+^-dependent glutamate release ([@B79]; [@B83]; [@B77]) ([Figure 1](#F1){ref-type="fig"}). Both InsP~3~Rs and RyRs were conduits for Ca^2+^ release from the ER to the cytosol ([@B77]). This was evident by the reduction of cytosolic Ca^2+^ loads and glutamate release when astrocytes were mechanically stimulated while being exposed to a variety of pharmacological agents including: (i) 2-APB (diphenylboric acid 2-aminoethyl ester), a cell-permeable InsP~3~R antagonist ([@B114]), which can also block the SOCE (store-operated Ca^2+^ entry) ([@B99]; [@B21]); (ii) ryanodine at concentration which can block RyRs ([@B168]; [@B73]; [@B64]); (iii) caffeine, which depletes the ER through persistent activation of RyRs, but can also block InsP~3~Rs ([@B129]; [@B204]; [@B48]); and (iv) combination of 2-APB with ryanodine or caffeine, without additive effect when compared with treatments with one agent only ([Figure 1](#F1){ref-type="fig"}).

![Sources of Ca^2+^ in Ca^2+^-dependent glutamate release from astrocytes\
The accumulation of Ca^2+^ in cytosol could be caused by the entry of Ca^2+^ from the ECS through: (i) L-type VGCC \[blocked by nifedipine (Nif)\]; (ii) SOCE via TRPC1 containing channels \[blocked by antibodies against the channel pore (Ab)\]; and (iii) the plasma membrane NCX (the reverse mode blocked by KB-R7943). The predominant source of Ca^2+^ is available from the ER internal store that possess InsP~3~R (blocked by 2-APB, which can also block SOCE) and RyR \[blocked by ryanodine (Ry)\] channels acting as conduits for Ca^2+^ delivery to the cytosol. The ER store is (re)filled by SERCA \[blocked by thapsigargin (Thaps)\]. Cytosolic Ca^2+^ levels are modulated by mitochondria that can take-up Ca^2+^ via the Ca^2+^ uniporter (blocked by Ru360) during the cytosolic Ca^2+^ increase. As cytosolic Ca^2+^ declines due to extruding mechanisms, Ca^2+^ is slowly released by mitochondria into cytosol via the mitochondrial NCX (blocked by CGP37157) as well as by the formation of the mitochondrial permeability transition pore \[its opening blocked by cyclosporin A (CsA)\]. The increase in cytosolic Ca^2+^ levels is sufficient and necessary to cause the fusion of glutamatergic vesicles to the plasma membrane and exocytotic release of glutamate. Drawing is not to scale.](an004e080f01){#F1}

An additional source of Ca^2+^ for gliotransmission comes from the ECS, since exposure of astrocytes to Cd^2+^, a broad spectrum blocker of plasmalemmal Ca^2+^ membrane channels, reduced both mechanically induced cytosolic Ca^2+^ loads and glutamate release ([@B77]), this finding being in agreement with the dual inhibitory action of 2-APB on the InsP~3~R and the SOCE. Indeed, SOCE, activated following the depletion of the ER Ca^2+^ store, is generally present in all types of glial cells (see e.g. [@B191]; [@B186]; [@B152]; [@B102]). Some of the possible SOCE molecular entities, the products of TRP (transient receptor potential) genes, have been identified in astrocytes and play a role in the regulation of astrocytic Ca^2+^ homoeostasis and glutamate release ([@B153]; [@B67]; [@B63]; [@B109]). Hence, an acute immunological treatment using blocking antibodies against the TRPC1 (TRP canonical 1) protein channel pore significantly reduced mechanically induced cytosolic Ca^2+^ elevations and the consequential glutamate release from cultured astrocytes ([@B109]) ([Figure 1](#F1){ref-type="fig"}).

In addition to SOCE, Ca^2+^ entry from the ECS to the cytosol can be mediated via plasma membrane voltage- and ligand-gated Ca^2+^ channels. Astrocytes in acute slices from ventrobasal thalamus showed intrinsic cytosolic Ca^2+^ oscillations which lead to glutamate release ([@B140]). These oscillations were thapsigargin sensitive, thus requiring Ca^2+^ release from the ER. However, they also required Ca^2+^ entry from the ECS since they were additionally sensitive to nifedipine, a blocker of L-type VGCC (voltage-gated Ca^2+^ channels) ([@B140]) ([Figure 1](#F1){ref-type="fig"}). Conversely, the L-type Ca^2+^ channel positive modulator BayK8644 increased the number of astrocytes exhibiting cytosolic Ca^2+^ oscillations ([@B139]). Although astrocytes *in vitro* and *in situ* express several types of plasma membrane ligand-gated Ca^2+^ channels/ionotropic receptors (for detailed overview, see [@B177]; [@B59]; [@B196]; [@B100]), their role in exocytotic glutamate release from astrocytes remains speculative at the moment.

An alternative pathway for *trans*-plasmalemmal Ca^2+^ movements is controlled by NCXs (Na^+^/Ca^2+^ exchangers), abundantly expressed in astrocytes ([@B61]; [@B183]; [@B115]; [@B90]). When operating in the reverse mode, the NCX can deliver Ca^2+^ to the cytosol ([@B90]; [@B166]). Hence, mild depolarization of astrocytes cultured from adult rats caused NCXs to operate in the reverse mode to generate cytosolic Ca^2+^ increases leading to glutamate release that were sensitive to 2-\[2-\[4-(4-nitrobenzyloxy)phenyl\]ethyl\]isothiurea (KB-R7943) ([@B131]) ([Figure 1](#F1){ref-type="fig"}). A similar role for NCX was observed when neonatal astrocytes were mechanically stimulated (Reyes and Parpura, 2009).

Cytosolic Ca^2+^ levels are also modulated by mitochondria ([@B45]). In mechanically stimulated astrocytes, mitochondria rapidly sequester high cytosolic Ca^2+^ via the Ca^2+^ uniporter. The inhibition of mitochondrial Ca^2+^ uniporters with Ru360 (Ruthenium 360) increased mechanically induced cytosolic Ca^2+^ loads and potentiated the release of glutamate ([@B163]) ([Figure 1](#F1){ref-type="fig"}). Conversely, as free cytosolic Ca^2+^ is removed by pumps, such as the SERCA and/or plasma membrane Ca^2+^ ATPase, mitochondria slowly release Ca^2+^ into cytosol via the mitochondrial NCX, as well as by the formation of the mitochondrial permeability transition pore. The inhibition of mitochondrial Ca^2+^ release, either by blocking the mitochondrial NCX with 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one (CGP37157) or by applying cyclosporin A which inhibits opening of the mitochondrial permeability transition pore ([@B10]), reduced both the cytosolic Ca^2+^ loads and consequential glutamate release ([@B165]) ([Figure 1](#F1){ref-type="fig"}).

Taken together multiple Ca^2+^ delivery/retrieval pathways are involved in regulating cytosolic Ca^2+^ levels, which are sufficient and necessary for triggering exocytotic release of glutamate, and/or other gliotransmitters, from astrocytes (reviewed in [@B135]). It should be noted, however, that the sensitivity of secretory machinery to cytosolic Ca^2+^ can be modulated ([@B28]; [@B209]), which has been recently demonstrated in cultured astrocytes ([@B164]).

Regulated exocytosis and gliotransmission
-----------------------------------------

The criteria for a chemical released from glia/astrocyte to be classified as a \'gliotransmitter\' have been defined ([@B43]; [@B203]; [@B112]; [@B135]) by a set of criteria: (i) synthesis by and/or storage in glia; (ii) regulated release triggered by physiological and/or pathological stimuli; (iii) activation of rapid (milliseconds to seconds) responses in neighbouring cells (paracrine), or to itself (autocrine); and (iv) a role in (patho)physiological processes. Astrocytes are capable of releasing a variety of gliotransmitters using three general mechanisms/conduits: (i) plasma membrane channels ([@B141]; [@B36]; [@B44]; [@B78]); (ii) plasma membrane transporters ([@B182]; [@B167]; [@B206]); and (iii) Ca^2+^-dependent exocytosis ([@B138]; [@B25]; [@B98]; [@B134]); also reviewed in [@B135]. Owing to the ongoing debate on the role of regulated exocytosis in gliotransmission ([@B176]), we here report on the exocytotic release of three classes of gliotransmitters: (i) amino acids, such as glutamate; (ii) nucleotides, such as ATP; and (iii) peptides, such as ANP (atrial natriuretic peptide).

Glutamate is synthesized within astrocytes via the tricarboxylic acid cycle ([@B207]). Owing to the expression of the enzyme pyruvate carboxylase, astrocytes can synthesize glutamate *de novo* ([@B74]). ATP is produced in cells by glycolysis and oxidative phosphorylation. Extracellularly released ATP can directly act on purinergic receptors, or indirectly, upon its hydrolysis by membrane-bound ectonucleotidases to ADP and adenosine, can activate various plasma membrane receptors (reviewed in [@B55]). Both glutamate and ATP get loaded into vesicular lumen by vesicular transporters (see below), unlike ANP which enters vesicles via the synthetic secretory pathway, i.e., pro-ANP is made in the ER, and after sorting into secretory vesicles it gets processed to its final form, ANP, before being released ([@B39]).

Ca^2+^-dependent exocytotic release of glutamate and ATP depends on the presence of two sets of proteins: (i) the SNARE (soluble *N*-ethylmaleimide-sensitive fusion protein-attachment protein receptor) complex, responsible for mediating vesicular and plasma membranes merger, containing: Sb2 (synaptobrevin 2), or its homologue cellubrevin, syntaxin 1, SNAP-23 (23 kDa synaptosome-associated protein); and (ii) proteins responsible for sequestering glutamate and ATP into vesicles: the V-ATPase (vacuolar type of proton ATPase), which drives protons into the vesicular lumen creating the proton concentration gradient necessary for glutamate/ATP transport into vesicles via VGLUTs (vesicular glutamate transporters) 1, 2 and 3 and VNUT (vesicular nucleotide transporter) respectively (reviewed in [@B121]; [@B135]) ([Figure 2A](#F2){ref-type="fig"}).

![Release of gliotransmitters from astrocytes\
(**A**) Ca^2+^-dependent glutamate release from astrocytes utilizes a vesicular exocytotic pathway, which can be inhibited by: (i) a holoprotein of tetanus toxin (TeTx) that cleaves vesicular SNAREs Sb2 and cellubrevin (Cb, red); (ii) bafilomycin A~1~ (BA~1~) a specific inhibitor of V-ATPase (brown) which pumps protons into the vesicular lumen; and (ii) Rose Bengal (RB), an allosteric site modulator of VGLUTs (pink), transporters that utilize proton gradient to deliver glutamate (Glu) into the vesicle. The plasma membrane SNAREs syntaxin 1 (green) and SNAP-23 (blue) form an acceptor complex for the vesicular SNARE (Sb2/Cb red). Scissors and arrows indicate sites of actions for agents affecting vesicular proteins. Drawing is not to scale. (**B**) Glutamatergic vesicles at the putative tripartite synapse. Immunoelectron micrograph of VGLUT1 (small gold particles) in astrocytic process (ast) is identified by the plasma membrane glutamate transporters labelling (large gold particles). VGLUT1 positive vesicles (insets, open arrowheads) in an astrocyte and in the adjacent neuronal terminal (ter) have similar appearances; m, mitochondria. Scale bars, 100 nm; and 50 nm in insets. Reprinted by permission from Macmillan Publishers Ltd: Nature Neuroscience, Paola Bezzi, Vidar Gundersen, José Luis Galbete, Gerald Seifert, Christian Steinhäuser et al., 2004, Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate, Nature Neuroscience, 7(6), pp. 613−620, copyright (2004). (**C**) Exocytotic release of ATP from astrocytes is quantal. Small transient inward currents (shaded in grey), representing quantal release, can be recorded from ATP-sensing HEK-293 cells cultured on astrocytes at rest (spontaneous release) and after these glial cells were stimulated with glutamate (open bar); stimulation significantly decreases the mean interval between detected currents. Reproduced from Tina Pangršič, Maja Potokar, Matjaž Stenovec, Marko Kreft, Elsa Fabbretti, Andrea Nistri, Evgeny Pryazhnikov, Leonard Khiroug, Rashid Giniatullin, Robert Zorec, Exocytotic Release of ATP from Cultured Astrocytes, Journal of Biological Chemistry, 282(39), pp 28749--28758. Copyright © 2007, by the American Society for Biochemistry and Molecular Biology. (**D**--**F**) Preferred vesicular fusion type in astrocytes is stimulus dependent. (**D**, **E**) Drawings depict two vesicle fusion types described in astrocytes: (**D**) transient fusion, where a vesicle remains intact and opens a transient fusion pore (arrow pointing down, fusion; arrow pointing up, vesicle retrieval from the plasma membrane); and (**E**) full fusion where a vesicle fully collapses into the plasma membrane upon fusion (arrow). (**F**) Fusion events, categorized as either transient or full fusions were plotted as a percentage of the total number of fusions that occurred, either spontaneously or when cultured astrocytes were exposed to various stimuli. Reproduced from Erik B. Malarkey and Vladimir Parpura, Temporal characteristics of vesicular fusion in astrocytes: examination of synaptobrevin 2-laden vesicles at singlevesicle resolution, Journal of Physiology, John Wiley and Sons © 2011 The Authors. Journal compilation © 2011 The Physiological Society.](an004e080f02){#F2}

Secretory vesicles are compulsory morphological elements for exocytosis; a large variety of their sizes has been reported in astrocytes (reviewed in [@B121]; [@B137]; [@B135]). In astrocytes, Sb2 can be associated with vesicular structures ranging from 30 to 700 nm, the majority of which are electron-lucent (clear), while ∼2% are dense core ([@B107]; [@B37]). Dense, and not so dense, core vesicles in cultured astrocytes with diameters of ∼115 nm, contained the secretory peptide secretogranin II ([@B25]) and ATP ([@B33]); subcellular fractions containing secretogranin II were mainly distinct from fractions containing Sb2 ([@B25]). Consistent with this finding ANP fluorescent derivative \[Emd (emerald green) appended\] puncta poorly co-localized with VGLUT1 signal ([@B97]), but they had ∼35% co-localization with ATP ([@B155]). However, ∼85% of Sb2 containing vesicles in astrocytes co-localize with VGLUTs ([@B120]; [@B23]); a subset of these Sb2 vesicles likely contains other transmitters such as [d]{.smallcaps}-serine ([@B113]). Astrocytes *in situ* showed association of cellubrevin and VGLUT 1 or 2 with small clear vesicles with a mean diameter of ∼30 nm ([@B17]) ([Figure 2B](#F2){ref-type="fig"}). However, photoconverted recycling dye FM1--43 labelled glutamatergic vesicles with a measured diameter of 310 nm which was comparable with their sizes in live cultured astrocytes (340 nm) obtained using differential interference contrast microscopy ([@B32]). Visualization of vesicles expressing the Sb2 fluorescent derivatives \[GFP (green fluorescent protein) or pHluorin appended\] in astrocytes using TIRFM (total internal reflection microscopy) gave an estimated diameter of under ∼100 nm ([@B23]) and of ∼312 nm (range 161--422 nm) ([@B108]). Similarly, diameters of VGLUT2 or VGLUT1-pHluorin expressing vesicles in astrocytes using TIRFM were estimated to be ∼40 nm ([@B26]; [@B111]). Glutamatergic vesicles labelled by capturing an extracellular antibody against VGLUT1 in a Ca^2+^-dependent manner while recycling with the plasma membrane are electron-lucent and have diameters of ∼50 nm ([@B179]). Similarly, recycling peptidergic vesicles, capturing an extracellular antibody against ANP, have diameters of ∼50 nm ([@B155]). Vesicles found within gliosomes, subcellular components of astrocytic processes isolated from brain by fractionation ([@B123]), express Sb2 and VGLUT1 and measure ∼30 nm in diameter ([@B181]). Taken together, it appears that there are three classes of vesicles devoted to packaging of amino acids, nucleotides and peptides with some overlap in co-packaging (see summary in Table 1 of [@B137]).

The process of exocytosis is characterized by quantal release of transmitter, which has been demonstrated in astrocytes using \'sniffer\' cells ([@B144]; [@B134]) and fluorescent microscopy ([@B17]; [@B134]) for ATP and glutamate, while glutamatergic vesicles containing a \'surrogate\' transmitter were also interrogated using amperometry ([@B32]). [@B144] transfected HEK-293 cells (human embryonic kidney cells), which endogenously do not express GluR, with NMDAR (*N*-methyl-[d]{.smallcaps}-aspartate receptor) subunits 1 and 2A. These cells, termed NR cells, were co-cultured with astrocytes and used as glutamate biosensors/reporters in whole-cell patch clamp recordings. Selective glutamatergic stimulation of astrocytes caused oscillatory \[Ca^2+^\]~i~ elevations in astrocytes as well as inward currents in adjacent NR cells consistent with quantal release of glutamate from astrocytes. Similarly, glutamate stimulation of astrocytes showed quantal release of ATP as recorded by ATP biosensor ([@B134]), HEK-293 cells expressing a mutated P2X~3~ receptor with reduced desensitization ([@B50]) ([Figure 2C](#F2){ref-type="fig"}). Further evidence for vesicular exocytosis from astrocytes came from the use of TIRFM ([@B17]; [@B134]). [@B134] incubated astrocytes with quinacrine, a compound that fluorescently labels ATP containing structures and shows punctate appearance. The rapid loss of quinacrine puncta was evident upon receptor stimulation using glutamate or ATP and the Ca^2+^ ionophore, ionomycin ([@B160]). Similar data were obtained for glutamatergic vesicles when astrocytes in culture were transfected to express either VGLUT 1-EGFP (enhanced GFP) or VGLUT 2-EGFP chimaeric proteins loaded with Acridine Orange and stimulated using a mGluR (metabotropic GluR) agonist or ionomycin ([@B17]). Additional evidence for quantal release from astrocytes was obtained by amperometric measurements from cells pre-incubated with the oxidizable transmitter dopamine, which was stored in glutamatergic vesicles ([@B32]). Exocytotic release of ANP, visualized as a disappearance of fluorescent chimaeric protein ANP-Emd puncta (quanta), was observed upon stimulation of astrocytes by ionomycin ([@B98]).

The delivery of secretory vesicles to the plasma membrane exocytotic sites can be observed as an increase in the C~m~ (membrane capacitance) due to a net addition of vesicular membrane to the plasma membrane ([@B97]). Hence, stimulation to increase \[Ca^2+^\]~i~ caused an increase in astrocyte C~m~ ([@B97]; [@B212]). Interestingly, in astrocytes the maximal rate of C~m~ increase (proportional to the rate of exocytosis) was at least two orders of magnitude slower when compared with that in neurons, measured by a similar method ([@B96]). In a subset of experiments where simultaneous measurements of glutamate release and C~m~ were made, evoked glutamate release from astrocytes was accompanied by an increase in C~m~ in all cells ([@B212]).

Using mainly neurons and chromaffin cells as models, two types of vesicle fusion have been described: (i) full fusion, where the vesicle collapses into the plasma membrane upon fusion ([Figure 2D](#F2){ref-type="fig"}), and (ii) transient fusion, where vesicles remain attached to the plasma membrane and transiently open the fusion pore ([Figure 2E](#F2){ref-type="fig"}). Both modes of exocytosis occur in astrocytes ([@B17]; [@B32]; [@B23]; [@B26]; [@B111]; [@B108]). Spontaneously occurring events had a similar ratio of transient to full fusions; the preference for one fusion type over the other was stimulus-dependent ([@B23]; [@B108]) ([Figure 2E](#F2){ref-type="fig"}). The consequence of transient versus full fusion on release of gliotransmitters critically depends on the measurements of the fusion pore. Such measurements would allow us to assess the amount and/or type of gliotransmitter (i.e., amino acid versus peptide) that could be released during transient fusion events ([@B193], [@B194]). In turn, such differential release properties of the two forms of vesicular release could have profound differential effects on astrocytic modulation of synaptic transmission and plasticity at the tripartite synapse ([@B5]).

Taken together, astrocytes possess functional secretory machinery for release of various gliotransmitters, which in turn can act upon neuronal receptors. The consequences of such gliotransmitter-mediated astrocyte--neuron signalling are further explored in upcoming sections below.

Mobility of secretory vesicles in astrocytes
--------------------------------------------

Ca^2+^-dependent exocytosis not only permits the exit of vesicle lumen cargo, such as gliotransmitters into the ECS, but also modifies important signalling membrane molecules, including transporters, receptors, exchangers and ion pumps, to be integrated by exocytosis into the plasma membrane where they can take part in the signal transduction. Thus, the understanding of vesicle traffic is crucial for uncovering the role astrocytes play in signal integration in the brain. Here, we will address vesicle traffic, vesicle delivery to and removal from the site of exocytosis, a highly complex set of processes at resting and stimulated conditions.

The traffic of vesicles likely evolved when eukaryotic cells emerged 1000--2000 million years ago ([@B210]). The evolution of these cells was associated with a cell volume increase by three to four orders of magnitude versus that of a typical prokaryotic cell. The increased cell size dictated a new organizational make-up. An important reason for this is that signalling and communication within the relatively large eukaryotic cell volume could no longer be supported mainly by diffusion-based processes. While the transport of ions and small molecules by diffusion in the sub-micrometre range is physiologically appropriate, the diffusional mobility of larger structures, such as vesicles, is predicted to be extremely slow, proportional to the aqueous diffusion coefficient and the inverse mass of the structure ([@B161]).

The first studies in astrocytes revealed two types of vesicular mobility, directional and non-directional ([@B154], [@B158]). Directional mobility was observed as vesicular tracks approximating straight-line appearance ([Figure 3A](#F3){ref-type="fig"}). In contrast to the non-directional type of vesicle mobility, the directional mobility failed to exhibit a linear relationship between the mean square displacement as a function of time ([Figure 3B](#F3){ref-type="fig"}), as is expected for diffusion-based processes, but was better described by a quadratic equation ([@B154]). Similar types of vesicle mobility were observed in other cell types ([@B24]; [@B192]; [@B47]; [@B75]). Vesicles exhibiting directional mobility are likely transported along the cytoskeleton: their mobility may be modulated by the dynamics of cytoskeletal elements, by different types of molecular motor proteins associated with the cytoskeleton, and by a variety of regulatory and signalling molecules ([@B31]).

![Vesicular mobility in astrocytes\
(**A--C**) Directional and non-directional vesicle mobility in resting astrocytes. (**A**) Examples of the mobility of vesicles, labelled by expressing the fluorescent ANP (pro-ANP-Emd) in astrocytes. Vesicles labelled with numbers 2 and 3 show directional mobility with elongated tracks (directional), whereas vesicles 1 and 4 exhibit non-directional mobility. Line on vesicle number 3 depicts the maximal displacement the vesicle attained in the observation time of 15 s. (**B**) Directional vesicles and (**C**) non-directional vesicles show the mean square displacement (MSD) of vesicle mobility as a function of time. Dashed line in (**B**) represents linear function (typical for a diffusion-based process) fitted to the data using equation: MSD (μm^2^) = (0.4702±0.0099)×Time(s). Upwardly curving line, which fits the data better than the linear function, represents quadratic function: MSD (μm^2^) = (0.2189±0.0148)×Time(s)+(0.0221±0.0013)×Time^2^(s^2^). In (**C**) a linear function was fitted to the data following the equation: \[MSD (μm^2^) = (0.0038±0.0001)×Time(s)\]. Reprinted from Biochem Biophys Res Commun, 329, Maja Potokar, Marko Kreft, Tina Pangršič, Robert Zorec, Vesicle mobility studied in cultured astrocytes, 678--683, Copyright 2005, with permission from Elsevier. (**D**, **E**) Post-fusion mobility of retrieved VGLUT1-positive vesicles in non-stimulated and stimulated astrocytes. Glutamatergic vesicles were fluorescently labelled by exposing the astrocytes to the extracellular antibody recognizing the vesicle luminal domain of the VGLUT1. Vesicle mobility was analysed by plotting vesicle maximal displacement (MD) as a function of the track length (TL). Numbered lines represent fits to the data (equations in left panel in grey). Stimulated cells (**E**) were treated with *Clostridium spiroforme* toxin (CST) to disintegrate actin filaments or left untreated (Con). Note that following the stimulation of cells by the addition of ionomycin to raise cytosolic calcium levels, increased vesicular mobility is seen as the steeper slope of the line (number 2). If cells were pretreated by the toxin CST the slope of the line (number 3) remained unchanged in comparison with controls (**D**, line number 1). (**D**, **E**) Reprinted from Experimental Cell Research, 313, Matjaž Stenovec et al., Ca^2+^-dependent mobility of vesicles capturing anti-VGLUT1 antibodies, 3809--3818, Copyright (2007), with permission from Elsevier.](an004e080f03){#F3}

In addition to microtubules and actin filaments as general cytoskeletal elements, astrocytes also express the IFs, such as GFAP, vimentin, nestin and synemin ([@B147]; [@B146]; [@B84]). It was shown that all three classes of cytoskeletal elements play a role in directional vesicle mobility in astrocytes ([@B158]). Unlike actin filaments and microtubules, IFs are devoid of enzymatic activity and are the least understood part of the cytoskeleton ([@B49]; [@B31]; [@B146]). While the first two types of IFs, GFAP and vimentin, form the IF cytoskeleton in non-reactive astrocytes in the adult brain ([@B146]), in reactive astrocytes, an increased expression of GFAP, vimentin, nestin and synemin filaments was reported ([@B49]; [@B84]). Since the characteristics of single vesicle traffic was first described in primary cultured astrocytes ([@B154]), a question often raised was how the overexpression of IFs in reactive astrocytes, under pathological conditions, affects vesicle dynamics, in particular, how the traffic of distinct types of vesicles is affected ([@B159], [@B156]).

In the initial studies, single vesicles were fluorescently labelled by expressing pro-ANP-Emd in cultured astrocytes ([@B154]). To describe vesicle mobility, parameters such as speed, step length, track length, maximal displacement and mean square displacement, were estimated. Vesicles containing recombinant peptide pro-ANP-Emd revealed directional mobility ([Figures 3A--3C](#F3){ref-type="fig"}) in 35% of vesicles ([@B154]), which is similar to the Sb2-EGFP tagged vesicles, where 25% of vesicles were highly mobile ([@B37]). It is likely that the directional mobility requires a cytoskeletal network, since disintegration of microtubules, actin filaments and IFs significantly reduced the population of vesicles exhibiting directional mobility ([@B158]). The role of IFs in vesicle traffic, where they appear to be required for long-range directional vesicle mobility, was unexpected, since these filaments were considered previously to primarily maintain the cell shape ([@B31]).

There was one other unexpected finding. After the vesicle membrane fuses with the plasma membrane transiently, the vesicle is thought to be retrieved into the cytoplasm ([@B80]; [@B184]). The mobility of retrieved vesicles was studied by labelling the vesicles with extracellular antibodies, which were captured when the vesicle lumen was temporarily exposed to the extracellular medium during transient vesicle fusion ([@B179]; [@B155]); a similar approach was used to label synaptic vesicles previously ([@B170]).

The mobility of retrieved vesicles differs from the peptidergic vesicle traffic to the plasma membrane, in the post-synthetic secretory pathway. First, the speed of retrieving ANP and VGLUT1 vesicles is one order of magnitude slower (∼0.05 μm/s) than the speed of peptidergic vesicles along the post-synthetic pathway towards the plasma membrane. These velocities are similar to that of ATP-containing vesicles ([@B134]; [@B155]). Secondly, while it has been reported that an increase in \[Ca^2+^\]~i~ does not cause a significant difference in the mean velocity of pro-ANP-Emd labelled vesicles before and after stimulation ([@B127]; [@B158]), the mobility of retrieved vesicles was altered following astrocyte stimulation by ionomycin to increase \[Ca^2+^\]~i~. The mobility of VGLUT1-positive vesicles was accelerated ([Figures 3D and 3E](#F3){ref-type="fig"}), while the mobility of ANP-positive vesicles was attenuated ([@B179]; [@B155]). However, as with the vesicle traffic along the post-synthetic pathway, the mobility of retrieved vesicles was reported to be sensitive to the disintegration of microtubules, actin filaments and IFs ([@B179]; [@B155]), consistent with results on the impaired traffic of vesicles carrying the GPCR (G-protein-coupled receptor) cannabiniod receptor 1 in astrocytes in which the dynamics of actin filaments or microtubules was perturbed ([@B128]).

To test that the vesicle mobility recorded in cultured astrocytes also occurs *in vivo*, vesicle dynamics was studied in brain slices in which cell-to-cell contacts are preserved and tissue architecture is closer to the one present in the brain ([@B157]). The mobility of specifically labelled recycling glutamatergic and peptidergic vesicles (immuno-positive for VGLUT1 or ANP respectively) was similar to that in cultured astrocytes ([@B179]; [@B155]).

To learn whether the accelerated/inhibited vesicle mobility requires the IFs, wild-type and double IF (GFAP^−/−^ and vimentin^−/−^) knock-out astrocytes were studied. The results have shown that the stimulus-accelerated mobility of VGLUT1-positive glutamatergic vesicles, and the stimulus-inhibited mobility of ANP-positive peptidergic vesicles was absent in astrocytes without IFs. Moreover, the stimulus-mediated-inhibition of endosome/lysosome mobility was absent in cells devoid of IFs ([@B159]). Thus, IFs play an important role in vesicle mobility regulation. One can thus expect that in reactive astrocytes, where IFs are overexpressed, this may differentially affect the stimulation-dependent mobility of recycling vesicles and endosomes ([@B156]). More direct evidence that pathological states in astrocytes may affect vesicle traffic was provided recently, where the mobility of endosomes/lysosomes in cultured astrocytes was increased upon the application of amyotrophic lateral sclerosis IgG ([@B180]).

In summary, recent studies of single vesicle traffic in astrocytes revealed complex properties of glutamatergic and peptidergic vesicle mobility and their specific responses to extracellular stimuli. It appears that all vesicle types in astrocytes do not respond to altered physiological and pathological conditions in the same pattern. This may represent a new cellular paradigm of how astrocytes contribute to the phenotype of brain function in physiological and pathological conditions. One of the key questions for the future is to learn about the molecular mechanisms that mediate stimulus-dependent vesicle mobility regulation. Moreover, we need further insights into the role of factors that affect vesicle mobility and whether these manifest at a more systemic level.

Astrocytes modulate synaptic transmission
-----------------------------------------

The elucidation of the functional consequences of gliotransmission on brain physiology has emerged as one of the most appealing topics in contemporary neuroscience. Astrocytes may release different neuroactive molecules, such as glutamate, [d]{.smallcaps}-serine, ATP, adenosine, GABA (γ-aminobutyric acid), TNFα (tumour necrosis factor α), prostaglandins, proteins and peptides that can potentially influence neuronal activity and synaptic physiology ([@B202]; [@B149]). Glutamate, one of the first recognized gliotransmitters originally identified in culture ([@B138]), has been shown to regulate synaptic transmission in cultured hippocampal cells ([@B3], [@B4]) and hippocampal slices. Glutamate released from astrocytes may exert multiple neuromodulatory actions on hippocampal synaptic transmission depending on the type of synapses, the neuronal sites of action and the subtypes of receptors activated. Astrocytic glutamate enhances the frequency of spontaneous and evoked excitatory synaptic currents through the activation of presynaptic group I mGluRs at hippocampal CA3--CA1 synapses ([@B126]; [@B105]; [@B148]; [@B124]) or presynaptic NMDARs at mossy fibres of the hippocampal dentate gyrus ([@B85]). It can also affect inhibitory transmission, inducing the potentiation ([@B86]) or depression of inhibitory synaptic currents by activation of presynaptic kainate ([@B104]) or group II/III mGluRs ([@B112]) respectively. The fact that a single gliotransmitter can exert multiple effects provides a high degree of complexity ([Figure 4](#F4){ref-type="fig"}) to the possible impact of the astrocyte--neuron communication on network function.

![Astrocytes modulate synaptic transmission\
Astrocyte calcium signal triggered by synaptic activity stimulates the release of different gliotransmitters, such as glutamate, ATP/adenosine or [d]{.smallcaps}-serine. These gliotransmitters act on specific glutamate α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), NMDAR and mGluR and adenosine (A~1~ and A~2A~) receptor types localized at the pre- or post-synaptic neurons. The consequently activated intracellular signalling pathways lead to depression or potentiation of synaptic transmission.](an004e080f04){#F4}

Besides glutamate, other gliotransmitters such as ATP and its metabolic product adenosine have also been shown to modulate synaptic transmission. The astrocytic release of ATP, which is converted into adenosine by extracellular nucleotidases, is responsible for the presynaptic A~1~ receptor activation that tonically depresses neurotransmission ([@B174]) and mediates heterosynaptic depression in hippocampal CA3--CA1 synapses ([@B211]; [@B133]; [@B174]). Adenosine itself directly released from astrocytes under hypoxic conditions has also been shown to down-regulate synaptic transmission in those synapses through activation of presynaptic A~1~ receptors ([@B112]). Furthermore, a more recent study has shown that basal synaptic transmission in CA3--CA1 synapses is up-regulated by the release of ATP/adenosine that tonically activates A~2A~ receptors ([@B132]). Again, as in the case of glutamate, these studies exemplify how a single gliotransmitter may have multiple and contrasting effects on synaptic transmission and, hence, in neural network function.

The fact that astrocytes may release different gliotransmitters and that a single gliotransmitter may act on different receptors and in different neuronal elements could provide apparent contradictory results. However, the existence of different regulatory effects should rather be regarded as complementary mechanisms that provide a high degree of complexity in the astrocytic control of the synaptic physiology. Experimental studies are generally designed to reveal the involvement of astrocytes in particular synaptic phenomena. However, the consequences of the astrocytic regulation of synaptic function can be much more complex in an actual neural network that is dynamically active because different neuromodulatory mechanisms can be simultaneously present. The influence of astrocytes, which are capable of releasing various gliotransmitters on synaptic transmission and neural network function, could be extremely diverse depending on the type of gliotransmitter released, the nature of the synapses involved, the type of neuronal receptors targeted as well as their pre- or post-synaptic localization. The temporal properties of these regulatory mechanisms may also be important. For example, sustained astrocytic purinergic signalling, which tonically up- or down-regulates synaptic activity through activation of A~1~ or A~2A~ receptors ([@B143]; [@B174]; [@B132]) may co-exist with a phasic glutamate signalling evoked by acute astrocytic calcium elevations that transiently potentiate synaptic transmission by activating presynaptic mGluRs ([@B54]; [@B148]; [@B124]) or NMDARs ([@B169]), which would provide higher degrees of freedom to the neural network activity.

Taken together, the functional consequences of astrocyte activity on synaptic function depend on the magnitude and spatial and temporal properties of the astrocyte calcium signal responsible for gliotransmitter release (i.e. which, when and where a type of gliotransmitter is released), as well as on the neuronal elements involved (i.e. what type of synapses, what type of receptors are activated and where in the pre- or post-synaptic membrane). At present we are gaining a better understanding of astrocyte involvement in synaptic physiology by revealing the possible regulatory mechanisms that may contribute to the astrocyte neuromodulation, but a detailed characterization of the physiological conditions, the astrocytic cellular code and the specific intercellular signalling that lead to the particular neuromodulation is necessary to coherently understand the actual consequences of synaptic transmission modulation by astrocyte activity on neural network function.

The astrocytic release of the gliotransmitter [d]{.smallcaps}-serine has also important consequences for the modulation of synaptic transmission properties. [d]{.smallcaps}-serine has been shown to be an endogenous ligand of the glycine-binding site of the NMDARs that acts as a co-agonist for these receptors and has important implications in glutamatergic transmission. In the hypothalamic supraoptic nucleus, changes in the astrocytic coverage of synapses under different physiological conditions result in changes in the ambient levels of [d]{.smallcaps}-serine released by astrocytes and its availability for NMDAR activation, thus influencing NMDAR-mediated synaptic responses ([@B133]).

Long-term synaptic changes, considered to represent the cellular mechanisms underlying learning and memory, can also be influenced in multiple forms by different gliotransmitters released from astrocytes. Some mechanisms are based on a tonic mode of action of astrocytic gliotransmitters that tonically and persistently regulate synaptic transmission ([@B174]; [@B178]; [@B72]; [@B132]). As a consequence of the above described modulation of NMDAR activity by astrocytic [d]{.smallcaps}-serine, astrocytes regulate the amplitude and direction of the synaptic plasticity in the supraoptic nucleus ([@B133]). Likewise, astrocytes in the CA1 area of the hippocampus control NMDAR-mediated synaptic plasticity through the release of [d]{.smallcaps}-serine ([@B72]). ATP/adenosine released from astrocytes has also been shown to govern the strength of the basal hippocampal synaptic activity by tonic suppression of neurotransmission, which results in an increase in the dynamic range for LTP (long-term potentiation) ([@B143]). In addition, astrocytes also participate in the generation of LTP in hippocampal CA3--CA1 synapses through a phasic signalling process, in which the temporal coincidence of the astrocyte calcium signal and the postsynaptic neuronal activity induces LTP through the activation of presynaptic group I mGluRs by calcium-dependent glutamate release from astrocytes ([@B148]).

Although most of the studies on synaptic transmission modulation by astrocytes have been performed on hippocampal slices because of their suitability as an experimental model to study synaptic transmission, synaptic regulation by astrocytes can be considered as a general phenomenon in the nervous system, as indicated by its presence in other brain areas, such as the retina, supraoptic nucleus and cerebellum, as well as in the PNS (peripheral nervous system) (for reviews, see [@B143]; [@B85]; [@B149]). However, to fully understand the role of astrocytes in brain function, it should be considered that astrocytes are largely interconnected cells through the expression of connexins, the membrane protein constituents of gap junction channels and hemichannels. Therefore, the existence of astroglial networks adds further complexity to the neuroglial networks underlying brain function ([@B60]).

In conclusion, accumulating evidence obtained during recent years has shown that astrocytes not only respond to neuronal activity but also actively modulate synaptic transmission and plasticity, demonstrating the existence of reciprocal communication between neurons and astrocytes. This evidence has led to the establishment of the concept for the tripartite synapse ([@B5]; [@B149]), which represents a novel functional view of synaptic physiology where astrocytes are relevant elements actively involved in synaptic function and neurophysiology.

Astrocytes modulate sleep homoeostasis through their control of adenosine
-------------------------------------------------------------------------

A significant challenge in studying the role of the astrocyte in brain function has been the development of strategies that allow one to determine how these glial cells regulate synapses, neural networks and ultimately behaviour. Towards these goals, it was necessary to develop various lines of astrocyte specific transgenic mice that allow the evaluation of the role of glial signalling pathways in the control of brain function ([@B143]; [@B53]). One such line in the dnSNARE (dominant negative SNARE) mouse expressing a cytosolic domain of Sb2 in astrocytes in the adult brain is due to conditional and selective transgenic targeting. Initial studies *in situ* using hippocampal slices revealed that the expression of dnSNARE in astrocytes led to an increase in the magnitude of excitatory synaptic transmission at the CA3--CA1 synapse ([@B143]). By performing pharmacological studies it was determined that this enhancement of synaptic transmission resulted from a reduction in the activation of presynaptic A~1~ receptors ([Figure 5](#F5){ref-type="fig"}) ([@B142]). It is well known that there is a basal level of extracellular adenosine that tonically exerts a presynaptic inhibition of synaptic transmission. Consequently, these results led to conclusion that astrocytic dnSNARE expression removed the source of adenosine, thereby enhancing synaptic transmission ([@B143]). Independent work using entirely different strategies ([@B174]) provided significant evidence in support of the notion that astrocytes can regulate extracellular adenosine.

![Pathways for synthesis, uptake and release of purines that may contribute to sleep homoeostasis\
Astrocytes release ATP through a SNARE-dependent mechanism. In the ECS, ectonucleotidases, such as CD73, can convert ATP into adenosine, which can be taken up by astrocytes via ENT. Intracellular adenosine can be converted into AMP or inosine by the action of ADK and ADA respectively. Astrocyte-mediated accumulation of extracellular adenosine leads to the activation of neuronal adenosine (A~1~) receptors resulting in modulation of synaptic transmission and sleep homoeostasis. Experimentally manipulated entities that support this model are shown in red. See text for additional details.](an004e080f05){#F5}

There are many pathways that regulate extracellular adenosine ([Figure 5](#F5){ref-type="fig"}). One possible pathway is mediated through the diffusion of adenosine down concentration gradients that is facilitated by plasma membrane ENTs (equilibrative nucleoside transporters). [@B143] tested the importance of this pathway by pharmacologically inhibiting the transporter and determining whether it led to altered adenosine-dependent signalling. Following inhibition, adenosine-mediated presynaptic inhibition was enhanced, a result that is consistent with the transporter normally being used to uptake adenosine from the extracellular to intracellular milieu. [@B143] therefore sought the identification of a different pathway of extracellular adenosine accumulation. One potential pathway is mediated by the release of ATP. Once released into the ECS ATP can be hydrolysed to adenosine by extracellular nucleotidases. Extracellular bioluminescence imaging studies demonstrated that astrocytic dnSNARE expression caused a reduction in extracellular ATP. Moreover, the addition of exogenous ATP rescued the normal adenosine tone in slices obtained from dnSNARE mice. Collectively, these results suggest that via a SNARE sensitive mechanism, presumably exocytosis, astrocytes release ATP which is hydrolysed in the ECS to adenosine. This adenosine modulates synaptic transmission and is cleared via uptake through ENTs ([Figure 5](#F5){ref-type="fig"}).

Having demonstrated that the astrocyte is critical for the control of adenosine, one can turn attention to potential behavioural phenotypes that result. It is well known that adenosine can modulate sleep ([@B9], [@B8]). For example, during wakefulness adenosine levels rise. Sleep deprivation leads to sustained adenosine elevations and infusion of adenosine promotes sleep. Additionally, adenosine receptor antagonists, including caffeine, promote wakefulness. The ability to selectively express dnSNARE only in astrocytes and thereby regulate the glial source of adenosine permitted investigations of whether astrocytes might modulate sleep systems.

There are two predominant modulators of sleep: the circadian oscillator that controls the timing of sleep and the sleep homoeostat that integrates the time awake and promotes sleep drive. Adenosine is implicated in the control of sleep homoeostasis. Using electroencephalography, [@B70] asked whether the astrocyte contributes to sleep homoeostasis. The drive to sleep can be assessed by measuring the power of SWA (slow wave activity) during non-rapid eye movement sleep. Following sleep deprivation, for example, SWA is enhanced. Under baseline conditions the power of SWA was reduced in dnSNARE mice and dnSNARE expression attenuated the responses to sleep deprivation. Following a period of sleep deprivation there is a compensatory increase in sleep time. Mice expressing dnSNARE in their astrocytes do not exhibit this increase of sleep time. Pharmacology performed *in vivo* demonstrated that inhibition of A~1~ receptors, the target of astrocyte-derived adenosine, phenocopied the dnSNARE phenotype ([@B70]) ([Figure 5](#F5){ref-type="fig"}).

This astrocyte adenosine mediated concept of the control of sleep homoeostasis is supported by additional studies. For example, mice with pan-cell knockout of the enzyme ecto-5′-nucleotidase, also known as CD73, necessary for extracellular hydrolysis of AMP to adenosine ([@B119]), as well as mice with conditional neuron-specific A~1~ receptor deletion both show similar sleep phenotypes to dnSNARE mice ([@B18]) ([Figure 5](#F5){ref-type="fig"}). Overexpression of ADK (adenosine kinase), an intracellular enzyme that is normally enriched in astrocytes and is responsible for the intracellular phosphorylation of adenosine to AMP, with concomitant conversion of ATP to ADP, leads to sleep phenotypes ([@B130]) ([Figure 5](#F5){ref-type="fig"}). Interestingly, humans with specific mutations in ADA (adenosine deaminase), which leads to reduced intracellular metabolism of adenosine to inosine, have an increased depth of sleep ([@B162]).

These results demonstrate the importance of adenosine and the astrocytic control of this purine in the control of sleep homoeostasis and point to the importance of these glial cells in the control of brain circuits underlying behaviour. Since many disorders of the brain have co-morbid sleep disorders it will be intriguing to determine the contribution of astrocytes to such disorders and whether targeting astrocytes could act as potential therapeutic strategies.

Astrocyte calcium and network modulation -- epilepsy
----------------------------------------------------

Although we are beginning to understand how deep and wide the impact of astrocyte-to-neuron signalling might be on neuronal functions in physiological conditions ([@B69]), an involvement of astrocytes in certain brain disorders is also gradually emerging ([@B110]; [@B172], [@B173]; [@B208]; [@B19]). One of the brain disorders in which astrocytes have been proposed to play a relevant role is epilepsy, a family of multifactorial brain diseases affecting at least 50 million people worldwide ([@B11]). The clinical manifestation of epilepsy is the seizure, a highly synchronous electrical discharge arising in a population of neurons from a relatively small region (i.e. the epileptogenic focus) that secondarily spreads across the brain by a progressive recruitment of other neuronal populations ([@B187]; [@B81]; [@B7]; [@B151]; [@B188]). Epilepsy can be considered a disorder of excessive synchronization of neurons, fundamentally linked to an imbalance between excitatory and inhibitory activities that produces a hyperexcitable neural network.

The hyperexcitable neuronal network that characterizes the epileptic brain is generally believed to originate from abnormalities intrinsic to neurons ([@B117]), but non-neuronal mechanisms may also contribute ([@B94]; [@B46]; [@B82]). A role of astrocytes as modulators of epileptogenesis was initially proposed over 20 years ago and for a long period it focused on the ability of astrocytes to buffer extracellular K^+^ or neurotransmitters (released in excess during epileptic discharges). Studies performed over the last decade, in both animal models and human epilepsy strengthened the view that a dysregulation of K^+^ buffering in the astrocyte network can predispose to neuronal hyperexcitability and contribute to establish an epileptic condition ([@B22]; [@B76]; [@B93]; [@B171]; [@B205]).

A more direct role of astrocytes in the generation of epileptiform activities was proposed only recently. The first clue for such a role came from demonstration that through the Ca^2+^-dependent glutamate release, and possibly [d]{.smallcaps}-serine ([@B122]; [@B133]), astrocytes can directly excite groups of neighbouring neurons and favour NMDAR-dependent synchronized activities ([@B52]). Following this observation, studies in brain slice preparations and *in vivo* reported a significant increase in the Ca^2+^ oscillation frequency in astrocytes during epileptiform activity ([@B185]; [@B51]), and its reduction in the presence of anticonvulsant drugs ([@B185]). The Ca^2+^-dependent glutamate release in astrocytes, and the consequent activation of extracellular NMDARs in neurons, was then found to contribute to cell loss in cortical and hippocampal regions during experimentally induced status epilepticus ([@B42]). In support of a direct astrocyte role in focal epilepsies, it was recently revealed that in the presence of the proconvulsant 4-aminopyridine astrocytes exhibited massive Ca^2+^ elevations upon an episode of intense neuronal activity ([@B106]) and by signalling back to neurons they generated a recurrent excitatory loop with neurons that had the potential to promote a focal seizure ([@B65]). Altogether, these results suggest that a hyperexcitable neuronal network may arise in the brain as a product of a dysregulation of local neuron-astrocyte reciprocal signalling and generate a focal site of seizure initiation.

Although these observations represent significant advances in our knowledge of the possible role of astrocytes in epilepsy, many important issues need to be defined. For example, the effect on epileptiform activities of other gliotransmitters, such as ATP, [d]{.smallcaps}-serine and GABA, or of inflammatory agents, such as cytokines and chemokines that are potentially released by activated astrocytes, has been not specifically addressed. Notably, not necessarily all these factors have proconvulsant effects. The observations that under physiological conditions adenosine derived from astrocytic ATP leads to inhibition of transmitter release and heterosynaptic depression by acting on presynaptic A~1~ receptors are, indeed, consistent with an anticonvulsant role of astrocytes. Also noteworthy is that seizure induction in experimental epilepsy was found to decrease adenosine extracellular concentrations through an up-regulation of astrocytic enzyme ADK that controls ambient adenosine levels ([@B20]), while genetic reduction of ADK was observed to prevent seizures ([@B103]). The overexpression of astrocytic ADK recently observed in hippocampal and cortical specimens from patients with temporal lobe epilepsy strengthens the hypothesis that a dysregulation of this enzyme in astrocytes is a hallmark of the chronic epileptic brain tissue ([@B6]).

The potential impact on seizure activity of astrocytes can be even more complex if we take into account that a gliotransmitter, such as glutamate, may affect not only excitatory but also inhibitory transmission ([@B86]; [@B14]). It follows that the overall effect of gliotransmission on the neuronal network excitability may ultimately depend not only on the type of gliotransmitter predominantly or selectively released but also on the distinct functional connectivity between astrocytes and different types of neurons from a specific brain region. As an excessive neuronal synchrony can arise as a result of inhibitory transmission impairment, it would be of great interest to understand whether a distinct signalling pathway exists between astrocytes and different GABAergic interneurons, and how it eventually changes in the epileptic brain tissue.

Astrocytes may contribute to epileptogenesis also through a number of different mechanisms. For example, a malfunction of the astrocytic plasma membrane glutamate transporters that critically control extracellular glutamate concentrations is a common feature in temporal lobe epilepsy. A recent study also revealed that the astrocytic plasma membrane GAT-1 (GABA transporter-1) likely has a central role in absence epilepsy ([@B34]). This form of non-convulsive epilepsy is characterized by synchronous spike-and-wave discharges arising in thalamo-cortical networks. In various well-established experimental models, the enhanced tonic inhibition, which in the ventrobasal thalamus crucially controls absence seizure generation, was regularly found to develop as a consequence of GAT-1 malfunction ([@B34]). As GAT-1 expression in the thalamus is mainly, if not exclusively, confined to astrocytes ([@B40]; [@B201]), these cells may be potential targets for the development of a new therapy in absence epilepsy.

A full clarification of the functional significance of the multiple signals that astrocytes exchange with neurons represents an intriguing challenge in the years to come. With a better understanding of astrocyte roles in both brain physiology and pathology, gliotransmission might be recognized as a target for developing new anti-epileptic therapies.

It is also worth underlining that the changes occurring in astrocyte signalling in the epileptic tissue may resemble the dysregulation of molecules and pathways that occur in other brain disorders. Indeed, astroglial GluRs and transporters, water channels (aquaporins), inward rectifier K^+^ channels and connexins were found to be dysregulated not only in epilepsy but also in motor-neuron disease, stroke, hepatic encephalopathy, schizophrenia, Huntington\'s disease and Alzheimer\'s disease ([@B19]; [@B110]; [@B172]). All in all, these studies suggest that astrocytes might hold the key to understand the pathogenesis of these brain disorders.

To improve our understanding we need, however, the results obtained from *in vitro* models to be validated in the intact brain. With the recent development of optogenetic tools to stimulate astrocytes selectively ([@B2]; [@B56]; [@B66]), and of new more sensitive, genetically encoded Ca^2+^ sensors, such as GCaMP3 ([@B175]), we have now the opportunity to study how astrocyte Ca^2+^ signalling can affect network activities in the living brain.

A full clarification of the functional significance of the multiple signals that astrocytes exchange with neurons represents an intriguing challenge in the years to come. With a better understanding of the astrocyte roles in both brain physiology and pathology, gliotransmission might be recognized as a target for developing new anti-epileptic therapies.

CONCLUDING REMARKS
==================

The intent of this review was to summarize the findings describing novel roles of astrocytes in the brain. Astrocytes can exocytotically release a variety of gliotransmitters under physiological and pathological conditions. This gliotransmission in turn can modulate synaptic transmission and plasticity and can also contribute to sleep behaviour. Although astrocytes can play a role in various disease states of the brain, as reviewed elsewhere ([@B197]), we solely focused on epilepsy in which astrocytic Ca^2+^ homoeostasis and gliotransmission can contribute to the aetiology of this disorder. Although these exciting findings shed new light on the brain operation in health and disease, featuring astrocytes as an integral component of brain\'s functions, they also raise many new issues that remain to be addressed. For example, how various release mechanisms for gliotransmitters operate under (patho)physiological conditions need to be systemically investigated. For vesicular gliotransmitter release alone, it would have to be determined how various gliotransmitters, individually and/or in blend(s), affect neurotransmission in different brain regions and account for different behaviours. It is clear at this juncture that such a colossal task would require the use of various levels of analysis, from single cells to the complex network in the living brain, and comprehensive utilization of a battery of experimental approaches, including molecular genetics, imaging, electrophysiology and behavioural testing.
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